

# Ellen M Lavoie Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5515674/publications.pdf>

Version: 2024-02-01

25  
papers

1,856  
citations

567281

15  
h-index

580821

25  
g-index

25  
all docs

25  
docs citations

25  
times ranked

2367  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 1941-1967.	1.6	976
2	Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 37-46.	3.1	150
3	Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. <i>Quality of Life Research</i> , 2013, 22, 2787-2799.	3.1	141
4	The Reliability and Validity of a Modified Total Neuropathy Score-Reduced and Neuropathic Pain Severity Items When Used to Measure Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxanes and Platinums. <i>Cancer Nursing</i> , 2010, 33, 173-183.	1.5	79
5	The Total Neuropathy Score: A Tool for Measuring Chemotherapy-Induced Peripheral Neuropathy. <i>Oncology Nursing Forum</i> , 2008, 35, 96-102.	1.2	74
6	Measuring Vincristine-Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. <i>Cancer Nursing</i> , 2013, 36, E49-E60.	1.5	67
7	Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. <i>Supportive Care in Cancer</i> , 2017, 25, 3537-3544.	2.2	52
8	The Validity of Neuropathy and Neuropathic Pain Measures in Patients With Cancer Receiving Taxanes and Platinums. <i>Oncology Nursing Forum</i> , 2011, 38, 133-142.	1.2	46
9	In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials. <i>Cancer Control</i> , 2018, 25, 107327481875660.	1.8	37
10	Acceptance and Use of Home-Based Electronic Symptom Self-Reporting Systems in Patients With Cancer: Systematic Review. <i>Journal of Medical Internet Research</i> , 2021, 23, e24638.	4.3	35
11	Nursing Knowledge, Practice Patterns, and Learning Preferences Regarding Chemotherapy-Induced Peripheral Neuropathy. <i>Oncology Nursing Forum</i> , 2014, 41, 669-679.	1.2	29
12	The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure. <i>Oncology Nursing Forum</i> , 2017, 44, 580-588.	1.2	25
13	Cancer Treatment-Related Neuropathic Pain Syndromes—Epidemiology and Treatment: An Update. <i>Current Pain and Headache Reports</i> , 2014, 18, 459.	2.9	22
14	Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data. <i>Cancer Nursing</i> , 2019, 42, 179-189.	1.5	22
15	Current Methods for the Assessment and Management of Taxane-Related Neuropathy. <i>Clinical Journal of Oncology Nursing</i> , 2013, 17, 22-34.	0.6	16
16	Proactive Rehabilitation for Chemotherapy-Induced Peripheral Neuropathy. <i>Seminars in Oncology Nursing</i> , 2020, 36, 150983.	1.5	15
17	Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy. <i>Seminars in Oncology Nursing</i> , 2019, 35, 253-260.	1.5	14
18	Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic review. <i>Lancet Haematology</i> , 2020, 7, e408-e417.	4.6	12

#	ARTICLE	IF	CITATIONS
19	Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire's Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data. <i>Supportive Care in Cancer</i> , 2019, 27, 2599-2608.	2.2	11
20	Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study. <i>Breast</i> , 2020, 51, 21-28.	2.2	9
21	Assessing Cancer Survivors's™ Needs Using Web-Based Technology. <i>CIN - Computers Informatics Nursing</i> , 2012, 30, 71-81.	0.5	8
22	Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2019, 6, 318-332.	1.6	7
23	Development and preliminary testing of the collaboration for leadership and innovation in mentoring survey: An instrument of nursing PhD mentorship quality. <i>Nurse Education Today</i> , 2021, 98, 104747.	3.3	4
24	Comparative assessment of ActiGraph data processing techniques for measuring sedentary behavior in adults with COPD. <i>Physiological Measurement</i> , 2021, 42, 085006.	2.1	4
25	Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 551-560.	2.5	1